160 related articles for article (PubMed ID: 23990113)
1. In vitro and in vivo therapeutic efficacy of carfilzomib in mantle cell lymphoma: targeting the immunoproteasome.
Zhang L; Pham LV; Newberry KJ; Ou Z; Liang R; Qian J; Sun L; Blonska M; You Y; Yang J; Lin X; Rollo A; Tamayo AT; Lee J; Ford RJ; Zhao X; Kwak LW; Yi Q; Wang M
Mol Cancer Ther; 2013 Nov; 12(11):2494-504. PubMed ID: 23990113
[TBL] [Abstract][Full Text] [Related]
2. Carfilzomib Inhibits Constitutive NF-κB Activation in Mantle Cell Lymphoma B Cells and Leads to the Induction of Apoptosis.
Zhang YL; Guang MH; Zhuo HQ; Min XH; Yao Q; Gu AQ; Wu SH; Zhang DB; Lu JY; Chen Y; Chen YH; Zhang KJ
Acta Haematol; 2017; 137(2):106-112. PubMed ID: 28208145
[TBL] [Abstract][Full Text] [Related]
3. Mucin 20 modulates proteasome capacity through c-Met signalling to increase carfilzomib sensitivity in mantle cell lymphoma.
Wang X; Shirazi F; Yan W; Liu X; Wang H; Orlowski RZ; Wang H
J Cell Mol Med; 2021 Nov; 25(21):10164-10174. PubMed ID: 34651428
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of Lyn is a promising treatment for mantle cell lymphoma with bortezomib resistance.
Kim A; Seong KM; Kang HJ; Park S; Lee SS
Oncotarget; 2015 Nov; 6(35):38225-38. PubMed ID: 26517678
[TBL] [Abstract][Full Text] [Related]
5. Carfilzomib interacts synergistically with histone deacetylase inhibitors in mantle cell lymphoma cells in vitro and in vivo.
Dasmahapatra G; Lembersky D; Son MP; Attkisson E; Dent P; Fisher RI; Friedberg JW; Grant S
Mol Cancer Ther; 2011 Sep; 10(9):1686-97. PubMed ID: 21750224
[TBL] [Abstract][Full Text] [Related]
6. Resistance of osteosarcoma cells to the proapoptotic effects of carfilzomib involves activation of mitogen activated protein kinase pathways.
Lei L; Zhang Y; Jian Q; Lei L; Lv N; Williamson RA; Chen P; Zhang D; Hu J
Exp Physiol; 2021 Feb; 106(2):438-449. PubMed ID: 33336554
[TBL] [Abstract][Full Text] [Related]
7. Novel treatment for mantle cell lymphoma including therapy-resistant tumor by NF-κB and mTOR dual-targeting approach.
Chaturvedi NK; Rajule RN; Shukla A; Radhakrishnan P; Todd GL; Natarajan A; Vose JM; Joshi SS
Mol Cancer Ther; 2013 Oct; 12(10):2006-17. PubMed ID: 23963361
[TBL] [Abstract][Full Text] [Related]
8. Combination of atiprimod and the proteasome inhibitor bortezomib induces apoptosis of mantle cell lymphoma in vitro and in vivo.
Sun L; Zhang L; Qian J; Yang J; Yi Q; Dong W; Wang M
Leuk Res; 2012 Mar; 36(3):363-8. PubMed ID: 22000823
[TBL] [Abstract][Full Text] [Related]
9. The therapeutic effects of rGel/BLyS fusion toxin in in vitro and in vivo models of mantle cell lymphoma.
Lyu MA; Pham LV; Sung B; Tamayo AT; Ahn KS; Hittelman WN; Cheung LH; Marks JW; Cho MJ; Ford RJ; Aggarwal BB; Rosenblum MG
Biochem Pharmacol; 2012 Aug; 84(4):451-8. PubMed ID: 22687624
[TBL] [Abstract][Full Text] [Related]
10. Obatoclax interacts synergistically with the irreversible proteasome inhibitor carfilzomib in GC- and ABC-DLBCL cells in vitro and in vivo.
Dasmahapatra G; Lembersky D; Son MP; Patel H; Peterson D; Attkisson E; Fisher RI; Friedberg JW; Dent P; Grant S
Mol Cancer Ther; 2012 May; 11(5):1122-32. PubMed ID: 22411899
[TBL] [Abstract][Full Text] [Related]
11. Pevonedistat, a NEDD8-activating enzyme inhibitor, is active in mantle cell lymphoma and enhances rituximab activity in vivo.
Czuczman NM; Barth MJ; Gu J; Neppalli V; Mavis C; Frys SE; Hu Q; Liu S; Klener P; Vockova P; Czuczman MS; Hernandez-Ilizaliturri FJ
Blood; 2016 Mar; 127(9):1128-37. PubMed ID: 26675347
[TBL] [Abstract][Full Text] [Related]
12. Synergistic activity of BET protein antagonist-based combinations in mantle cell lymphoma cells sensitive or resistant to ibrutinib.
Sun B; Shah B; Fiskus W; Qi J; Rajapakshe K; Coarfa C; Li L; Devaraj SG; Sharma S; Zhang L; Wang ML; Saenz DT; Krieger S; Bradner JE; Bhalla KN
Blood; 2015 Sep; 126(13):1565-74. PubMed ID: 26254443
[TBL] [Abstract][Full Text] [Related]
13. Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma.
Kuhn DJ; Chen Q; Voorhees PM; Strader JS; Shenk KD; Sun CM; Demo SD; Bennett MK; van Leeuwen FW; Chanan-Khan AA; Orlowski RZ
Blood; 2007 Nov; 110(9):3281-90. PubMed ID: 17591945
[TBL] [Abstract][Full Text] [Related]
14. Second generation proteasome inhibitors: carfilzomib and immunoproteasome-specific inhibitors (IPSIs).
Kuhn DJ; Orlowski RZ; Bjorklund CC
Curr Cancer Drug Targets; 2011 Mar; 11(3):285-95. PubMed ID: 21247387
[TBL] [Abstract][Full Text] [Related]
15. The novel β2-selective proteasome inhibitor LU-102 decreases phosphorylation of I kappa B and induces highly synergistic cytotoxicity in combination with ibrutinib in multiple myeloma cells.
Kraus J; Kraus M; Liu N; Besse L; Bader J; Geurink PP; de Bruin G; Kisselev AF; Overkleeft H; Driessen C
Cancer Chemother Pharmacol; 2015 Aug; 76(2):383-96. PubMed ID: 26099967
[TBL] [Abstract][Full Text] [Related]
16. Carfilzomib-dependent selective inhibition of the chymotrypsin-like activity of the proteasome leads to antitumor activity in Waldenstrom's Macroglobulinemia.
Sacco A; Aujay M; Morgan B; Azab AK; Maiso P; Liu Y; Zhang Y; Azab F; Ngo HT; Issa GC; Quang P; Roccaro AM; Ghobrial IM
Clin Cancer Res; 2011 Apr; 17(7):1753-64. PubMed ID: 21355079
[TBL] [Abstract][Full Text] [Related]
17. Mantle cell lymphoma: taking therapeutic advantage of new insights into the biology.
Tang T; Martin P
Curr Hematol Malig Rep; 2014 Sep; 9(3):254-61. PubMed ID: 25023397
[TBL] [Abstract][Full Text] [Related]
18. Second-generation proteasome inhibitor carfilzomib enhances doxorubicin-induced cytotoxicity and apoptosis in breast cancer cells.
Shi Y; Yu Y; Wang Z; Wang H; Bieerkehazhi S; Zhao Y; Suzuk L; Zhang H
Oncotarget; 2016 Nov; 7(45):73697-73710. PubMed ID: 27655642
[TBL] [Abstract][Full Text] [Related]
19. A lowered 26S proteasome activity correlates with mantle lymphoma cell lines resistance to genotoxic stress.
Ben Younes K; Body S; Costé É; Viailly PJ; Miloudi H; Coudre C; Jardin F; Ben Aissa-Fennira F; Sola B
BMC Cancer; 2017 Aug; 17(1):538. PubMed ID: 28797244
[TBL] [Abstract][Full Text] [Related]
20. Prevalence of bortezomib-resistant constitutive NF-kappaB activity in mantle cell lymphoma.
Yang DT; Young KH; Kahl BS; Markovina S; Miyamoto S
Mol Cancer; 2008 May; 7():40. PubMed ID: 18489772
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]